Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.66 |
| ▸ | MAPT | P10636 | 4/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.59 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 5/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CA4 | P22748 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | MAOA | P21397 | 2/20 | 0.54 |
| ▸ | MAOB | P27338 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1781435 | 0.87 | GAA (0.61) | ALDH1A1MAPTTDP1GAAHSP90AA1 | |
| SCHEMBL1779254 | 0.87 | ALDH1A1 (0.61) | ALDH1A1MAPTTDP1GAAHSP90AA1 | |
| SCHEMBL1780301 | 0.87 | TSHR (0.60) | ALDH1A1MAPTTDP1GAAHSP90AA1 | |
| SCHEMBL19545037 | 0.84 | DHFR (0.49) | ALDH1A1MAPTTDP1GAAHSP90AA1 | |
| SCHEMBL17838915 | 0.84 | HPGD (0.70) | ALDH1A1MAPTTDP1GAAHSD17B10 | |
| SCHEMBL10025780 | 0.84 | TSHR (0.63) | ALDH1A1MAPTTDP1GAAHSP90AA1 | |
| SCHEMBL1782829 | 0.84 | ALDH1A1 (0.58) | ALDH1A1MAPTTDP1GAAHSP90AA1 | |
| SCHEMBL1782848 | 0.82 | ALDH1A1 (0.59) | ALDH1A1MAPTTDP1GAAHSP90AA1 | |
| SCHEMBL10025782 | 0.82 | MAPT (0.59) | ALDH1A1MAPTTDP1GAAHSP90AA1 | |
| SCHEMBL1783346 | 0.82 | ALDH1A1 (0.59) | ALDH1A1MAPTTDP1GAAHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210290623-A1 | METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS | DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) | 2021-09-23 | — | — | US | claimed |
| EP-3833336-A1 | METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES | DalCor Pharma UK Ltd Leatherhead, Zug Branch (CH) | 2021-06-16 | — | — | EP | claimed |
| WO-2020030814-A1 | METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES | DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) | 2020-02-13 | — | — | WO | claimed |
| US-20190070178-A1 | METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS | DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) | 2019-03-07 | — | — | US | claimed |
| WO-2019043018-A1 | METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS | DALCOR PHARMA UK LTD., STOCKPORT ZUG BRANCH (CH) | 2019-03-07 | — | — | WO | claimed |
| US-8592430-B2 | Quinazolin-oxime derivatives as Hsp90 inhibitors | DAC SLR (IT) | 2013-11-26 | — | — | US | claimed |
| EP-2144889-B1 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC SRL (IT) | 2012-08-29 | — | — | EP | claimed |
| US-20110118258-A1 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC SRL (IT) | 2011-05-19 | — | — | US | claimed |
| US-20210290623-A1 | METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS | DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) | 2021-09-23 | — | — | US | disclosed |
| US-20210236442-A1 | METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES | DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) | 2021-08-05 | — | — | US | disclosed |
| EP-3833336-A1 | METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES | DalCor Pharma UK Ltd Leatherhead, Zug Branch (CH) | 2021-06-16 | — | — | EP | disclosed |
| US-20200222406-A1 | METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS | DALCOR PHARMA UK LTD., STOCKPORT ZUG BRANCH (CH) | 2020-07-16 | — | — | US | disclosed |
| WO-2020030814-A1 | METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES | DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) | 2020-02-13 | — | — | WO | disclosed |
| WO-2019043018-A1 | METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS | DALCOR PHARMA UK LTD., STOCKPORT ZUG BRANCH (CH) | 2019-03-07 | — | — | WO | disclosed |
| US-20110118258-A1 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC SRL (IT) | 2011-05-19 | — | — | US | disclosed |
| US-20110118258-A1 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC SRL (IT) | 2011-05-19 | — | — | US | disclosed |
| US-20110118258-A1 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC SRL (IT) | 2011-05-19 | — | — | US | disclosed |
| EP-2144889-A2 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC S.r.l. (IT) | 2010-01-20 | — | — | EP | disclosed |
| WO-2008142720-A2 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC SRL (IT) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008142720-A2 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC SRL (IT) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210236442-A1 | METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES | IAPP, SLC5A2, SLC2A2 | ALDH1A1 3985/4885MAPT 2857/4885TDP1 3903/4885 |
| US-20110118258-A1 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | HSP90AB1, HSP90AA1, HSP90B1 | ALDH1A1 1998/4885MAPT 296/4885TDP1 287/4885 |
| US-20200222406-A1 | METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS | HMGCR, PCSK9, FABP3 | ALDH1A1 1235/4885MAPT 3073/4885TDP1 1557/4885 |
| US-20190070178-A1 | METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS | HMGCR, PCSK9, FABP3 | ALDH1A1 1235/4885MAPT 3073/4885TDP1 1557/4885 |
| US-20210290623-A1 | METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS | HMGCR, PCSK9, FABP3 | ALDH1A1 1235/4885MAPT 3073/4885TDP1 1557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.